Sansure Biotech Inc. (SHA:688289)
China · Delayed Price · Currency is CNY 16.08
+0.18 (1.13%)
Sep 14, 2026, 3:00 PM CST
Sansure Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,140 | 10,858 | 13,001 | 11,187 | 12,747 | 23,600 | |
Market Cap Growth | -22.42% | -16.48% | 16.22% | -12.24% | -45.99% | -48.22% |
Enterprise Value | 6,925 | 8,045 | 8,982 | 6,408 | 7,417 | 18,716 |
Last Close Price | 15.90 | 18.57 | 21.70 | 18.21 | 19.68 | 34.25 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 69.04 | 54.58 | 47.17 | 30.76 | 6.58 | 10.52 |
Forward PE | 36.41 | 26.22 | 35.75 | 51.11 | 8.19 | 12.20 |
PS Ratio | 5.69 | 6.61 | 8.92 | 11.11 | 1.98 | 5.23 |
PB Ratio | 1.29 | 1.51 | 1.77 | 1.51 | 1.70 | 3.70 |
P/TBV Ratio | 1.61 | 1.87 | 1.88 | 1.62 | 1.72 | 3.73 |
P/FCF Ratio | - | - | - | - | 6.37 | 15.69 |
P/OCF Ratio | 29.38 | 59.02 | 47.37 | 256.93 | 4.98 | 12.57 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.31 | 4.90 | 6.16 | 6.36 | 1.15 | 4.15 |
EV/EBITDA Ratio | 24.34 | 23.98 | 33.30 | 80.30 | 3.27 | 7.28 |
EV/EBIT Ratio | 136.72 | 60.10 | 70.58 | - | 3.38 | 7.41 |
EV/FCF Ratio | - | - | - | - | 3.71 | 12.44 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.22 | 0.16 | 0.06 | 0.01 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 5.36 | 3.28 | 1.52 | 0.40 | 0.01 | 0.01 |
Debt / FCF Ratio | - | - | - | - | 0.01 | 0.01 |
Net Debt / Equity Ratio | -0.32 | -0.42 | -0.59 | -0.64 | -0.75 | -0.73 |
Net Debt / EBITDA Ratio | -8.30 | -8.94 | -15.97 | -59.44 | -2.48 | -1.81 |
Net Debt / FCF Ratio | 39.22 | 16.14 | 29.37 | 13.64 | -2.82 | -3.10 |
Asset Turnover | 0.17 | 0.18 | 0.17 | 0.11 | 0.79 | 0.72 |
Inventory Turnover | 0.99 | 1.04 | 0.73 | 0.77 | 8.04 | 3.97 |
Quick Ratio | 4.18 | 3.97 | 7.05 | 5.98 | 4.48 | 8.29 |
Current Ratio | 4.67 | 4.37 | 7.67 | 6.47 | 4.79 | 8.99 |
Return on Equity (ROE) | 1.28% | 2.12% | 3.06% | 4.66% | 27.88% | 40.31% |
Return on Assets (ROA) | 0.33% | 0.92% | 0.93% | -0.15% | 16.86% | 25.17% |
Return on Invested Capital (ROIC) | 1.01% | 3.26% | 3.86% | -0.78% | 102.20% | 186.47% |
Return on Capital Employed (ROCE) | 0.60% | 1.60% | 1.60% | -0.30% | 28.90% | 39.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.47% | 1.83% | 2.12% | 3.25% | 15.19% | 9.50% |
FCF Yield | -0.64% | -1.71% | -1.13% | -3.11% | 15.69% | 6.37% |
Dividend Yield | 3.31% | 2.82% | 2.42% | 2.54% | 6.59% | 2.22% |
Payout Ratio | 245.06% | 167.73% | 97.39% | 110.10% | 33.92% | 19.61% |
Buyback Yield / Dilution | 0.67% | 0.22% | 0.05% | -0.26% | 0.59% | -6.55% |
Total Shareholder Return | 3.98% | 3.03% | 2.47% | 2.28% | 7.19% | -4.33% |